Ratings Bionomics Australian S.E.

Equities

BNO

AU000000BNO5

Delayed Australian S.E. Other stock markets 02:10:06 2023-08-24 am EDT			5-day change	1st Jan Change
0.01 ^AUD	-.--%		-.--%	-.--%

May. 31	Bionomics Limited announced that it expects to receive $70 million in funding	CI
Mar. 21	Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	CI

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIONOMICS	-.--%	9.94M	C-
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B	B+
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B	B+
ARGENX SE	+25.56%	27.95B	B
BIONTECH SE	-19.51%	20.5B	B+
GENMAB A/S	-14.36%	17.12B	A-
BEIGENE, LTD.	-15.63%	16.1B	B
WUXI APPTEC CO., LTD.	-46.67%	14.97B	A-
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B	C+
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes